Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Sells $103,147.50 in Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 4,250 shares of the company’s stock in a transaction that occurred on Friday, September 27th. The shares were sold at an average price of $24.27, for a total transaction of $103,147.50. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Benjamin Hohl also recently made the following trade(s):

• On Monday, September 30th, Benjamin Hohl sold 2,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $25.33, for a total transaction of $50,660.00.
• On Tuesday, August 27th, Benjamin Hohl sold 4,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $22.54, for a total transaction of $95,795.00.
• On Wednesday, July 31st, Benjamin Hohl sold 991 shares of Enliven Therapeutics stock. The shares were sold at an average price of $27.53, for a total transaction of $27,282.23.
• On Monday, July 29th, Benjamin Hohl sold 5,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $26.68, for a total transaction of $140,070.00.
• On Friday, July 12th, Benjamin Hohl sold 3,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $25.07, for a total transaction of $75,210.00.

Enliven Therapeutics Stock Performance

Shares of NASDAQ ELVN opened at $25.51 on Friday. The company’s fifty day moving average price is $23.20 and its 200 day moving average price is $21.86. Enliven Therapeutics, Inc. has a 1 year low of $9.80 and a 1 year high of $27.67. The company has a market capitalization of $1.20 billion, a PE ratio of -13.22 and a beta of 1.09.

Enliven Therapeutics (NASDAQ:ELVN) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($0.41) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.17. On average, equities analysts expect that Enliven Therapeutics, Inc. will post -1.98 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on ELVN. HC Wainwright reiterated a “buy” rating and issued a $37.00 price objective on shares of Enliven Therapeutics in a research note on Tuesday. Baird R W upgraded shares of Enliven Therapeutics to a “strong-buy” rating in a research note on Tuesday, June 11th. Finally, Robert W. Baird assumed coverage on shares of Enliven Therapeutics in a research note on Tuesday, June 11th. They issued an “outperform” rating and a $32.00 price objective on the stock.

Hedge Funds Weigh In On Enliven Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Quest Partners LLC lifted its holdings in Enliven Therapeutics by 87.3% during the second quarter. Quest Partners LLC now owns 1,592 shares of the company’s stock valued at $37,000 after purchasing an additional 742 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in Enliven Therapeutics by 67.0% during the first quarter. China Universal Asset Management Co. Ltd. now owns 7,952 shares of the company’s stock valued at $140,000 after purchasing an additional 3,189 shares in the last quarter. EntryPoint Capital LLC purchased a new position in Enliven Therapeutics during the first quarter valued at $167,000. SG Americas Securities LLC purchased a new position in Enliven Therapeutics during the third quarter valued at $256,000. Finally, The Manufacturers Life Insurance Company purchased a new position in Enliven Therapeutics during the second quarter valued at $322,000. 95.08% of the stock is owned by hedge funds and other institutional investors.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.